eFFECTOR Stock To Rally Over 500%? Analyst Predict Blockbuster Status For Cancer Candidates
Portfolio Pulse from Vandana Singh
HC Wainwright has initiated coverage on eFFECTOR Therapeutics Inc (EFTR) with a Buy rating and a price target of $5. The analysts highlight eFFECTOR's lead candidate, zotatifin, and another potential value driver, tomivosertib, which could reach the market by 2027 and achieve blockbuster status by 2030. A collaboration with Pfizer Inc (PFE) provides strategic validation and potential long-term upside. EFTR shares are currently trading flat at $0.71.
August 24, 2023 | 6:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
eFFECTOR Therapeutics has received a Buy rating from HC Wainwright, with a price target of $5. The company's lead candidates, zotatifin and tomivosertib, are expected to reach the market by 2027 and achieve blockbuster status by 2030.
The Buy rating and price target of $5 from HC Wainwright could attract more investors to EFTR, potentially driving up the stock price. The positive outlook for the company's lead candidates also adds to the bullish sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pfizer's collaboration with eFFECTOR Therapeutics provides strategic validation and potential long-term upside.
Pfizer's collaboration with eFFECTOR Therapeutics could potentially lead to new revenue streams and strengthen its position in the oncology market. This could have a positive impact on PFE's stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50